Stentoft J, Jensen M K
Eur J Haematol. 1987 Mar;38(3):284-7. doi: 10.1111/j.1600-0609.1987.tb01178.x.
5 heavily pretreated patients with chronic lymphocytic leukaemia or non-Hodgkin lymphoma resistant to alkylating agents were treated with low-dose cytosine arabinoside (ARA-C). 3 of the patients showed a clinical and laboratory improvement lasting from 8 to more than 20 months. Low dose ARA-C may be therapeutically effective in terminal stages of lymphoproliferative disorders.
5例对烷化剂耐药的慢性淋巴细胞白血病或非霍奇金淋巴瘤的重度预处理患者接受了小剂量阿糖胞苷（ARA-C）治疗。其中3例患者出现了持续8至20多个月的临床和实验室改善。小剂量阿糖胞苷可能对淋巴增殖性疾病的终末期具有治疗效果。
